Aytu Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

• Aytu Biopharma Inc AYTU.OQ reported quarterly adjusted earnings of 44 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.48. The lone analyst forecast for the quarter was for a loss of 34 cents per share.

• Revenue fell 25% to $16.57 million from a year ago; analysts expected $13.77 million.

• Aytu Biopharma Inc's reported EPS for the quarter was 24 cents​.

• The company reported quarterly net income of $1.47 million.

• Aytu Biopharma Inc shares had fallen by 25.7% this quarter and lost 38.6% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00

This summary was machine generated from LSEG data November 14 at 09:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)